ArticleLe infezioni in medicina2024
Seroprevalence of Crimean-Congo hemorrhagic fever virus in the population of Turkestan region.
Article in Le infezioni in medicina, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Integrated surveillance, virus isolation and phylogenetic characterization of Crimean-Congo hemorrhagic fever virus in Central Kazakhstan.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the level of seroprevalence to the virus of Crimean-Congo Hemorrhagic Fever (CCHF) in population of rural area of the particular districts of Turkestan region, Kazakhstan and its connection with epidemiological alerts. Materials and methods: For determining the real Crimean-Congo hemorrhagic fever virus (CCHFV) circulation in Turkestan region, Kazakhstan, massive sero-epidemiologic studies were conducted. Healthy residents of Turkestan Region aged from 10 to 75 years were examined without having been previously registered with CCHF. After receiving an informed consent, 5 ml of venous blood was collected for ELISA assay using the following test kits: VectoCrimea-CHF-IgG and VectoCrimea-CHF-IgM by the Vector-Best JSC. Findings on CCHF morbidity rate along with prevalence of ticks were received from the reports of the Committee of Sanitary and Epidemiological Control of the Ministry of Healthcare of the Republic of Kazakhstan. Results: Blood serum samples were collected prospectively from 4259 residents in all 16 districts of rural areas of Turkestan region. CCHF seroprevalence was detected in 2.39% of cases. Anamnesis of a tick-bite along with livestock contact in 18-30 years and 41-50 years age groups were considered as risk factors. The highest rate of CCHF seroprevalence was determined in the following recognized endemic regions and districts, namely Sozak District (4.04%), Turkestan Region (3.85%), Jetisu Region (3.6%). Reactivity probes were detected in residents of all 16 districts of Turkestan Region. The research statistics displayed that CHHF pathogen considerably increased its circulation in the endemic regions and the disease communicated into a number of new districts. Conclusion: IgG ELISA was performed to screen CCH-FV in 4259 village inhabitants of Turkestan Region and revealed the presence of antibodies in 2.39% of its population. Weak linear correlation relationship was established between CCHFV seroprevalence rate and CCH-FV morbidity rate in the particular districts of Turkestan Region. As people grow older, CCHFV IgG detection rate increases. Living on CHHF endemic territories is a serious risk factor to become CHHF positive which is characterized by manifestation of the subclinical forms of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.